ChristianaCare Gene Editing Institute

CRISPR breakthrough reverses chemotherapy resistance in lung cancer

Researchers have shown that disabling the NRF2 gene with CRISPR technology can restore drug sensitivity and slow tumor growth in lung cancer. The approach, which targets a master switch for resistance, has potential across multiple tumor types.

SourceChristianaCare Gene Editing Institute·JournalMolecular Therapy Oncology·TypeExperimental study·DateNov 17, 2025

Scientists at ChristianaCare gene editing institute use CRISPR tools to safely disable gene mutation linked to treatment-resistant melanoma

Researchers at ChristianaCare Gene Editing Institute use CRISPR tools to safely disable gene mutation linked to treatment-resistant melanoma. The approach targets melanoma tumor cells while leaving healthy cells alone, restoring sensitivity to anticancer drugs.

SourceChristianaCare Gene Editing Institute·JournalThe CRISPR Journal·DateOct 15, 2024

Scientists put CRISPR on safer path to patient treatments with new process for evaluating impacts of gene edits that alter rather than “knock out” DNA code

Researchers at ChristianaCare's Gene Editing Institute describe a new process for evaluating the impacts of gene edits that alter rather than completely disabling DNA code. The study validates the safety and efficacy of their novel approach for using CRISPR to improve lung cancer treatments.

SourceChristianaCare Gene Editing Institute·JournalGene Therapy·TypeExperimental study·DateMar 21, 2022